HOME
CAREER NETWORK
NEWS
HOTBEDS
EVENT CENTER
CAREER FAIRS
COMPANY PROFILES
RESEARCH STORE
ABOUT US
NEWSLETTERS Free Newsletters Archive My Subscriptions NEWS News by Subject News by Disease News by Date PLoS Search News Post Your News JoVE CAREER NETWORK Job Seeker Login Most Recent Jobs Browse Biotech Jobs Search Jobs Post Resume Career Fairs Career Resources For Employers HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia DIVERSITY INVESTOR Market Summary News IPOs PROFILES Company Profiles START UPS Companies Events INTELLIGENCE Research Store INDUSTRY EVENTS Biotech Events Post an Event RESOURCES Real Estate Business Opportunities
by Niall F. Davis, Rory Mooney, Anthony Callanan, Hugh D. Flood, Tim M. McGloughlin
Augmentation cystoplasty (AC) with autogenous ileum remains the current gold standard surgical treatment for many patients with end-stage bladder disease. However, the presence of mucus-secreting epithelium within the bladder is associated with debilitating long-term complications. Currently, decellularised biological materials derived from porcine extracellular matrix (ECM) are under investigation as potential augmentation scaffolds. Important biomechanical limitations of ECMs are decreased bladder capacity and poor compliance after implantation.
In the present ex vivo study a novel concept was investigated where a two-fold increase in ECM scaffold surface-area relative to the resected ileal segment was compared in ovine bladder models after AC. Results showed that bladder capacity increased by 40±4% and 37±11% at 10 mmHg and compliance by 40.4±4% and 39.7±6% (?P?=?0–10 mmHg) after AC with ileum and porcine urinary bladder matrix (UBM) respectively (p<0.05). Comparative assessment between ileum and UBM demonstrated no significant differences in bladder capacity or compliance increases after AC (p>0.05).
These findings may have important clinical implications as metabolic, infective and malignant complications precipitated by mucus-secreting epithelium are potentially avoided after augmentation with ECM scaffolds.